384 related articles for article (PubMed ID: 9792158)
1. Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours.
Baudin E; Gigliotti A; Ducreux M; Ropers J; Comoy E; Sabourin JC; Bidart JM; Cailleux AF; Bonacci R; Ruffié P; Schlumberger M
Br J Cancer; 1998 Oct; 78(8):1102-7. PubMed ID: 9792158
[TBL] [Abstract][Full Text] [Related]
2. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones.
Nobels FR; Kwekkeboom DJ; Coopmans W; Schoenmakers CH; Lindemans J; De Herder WW; Krenning EP; Bouillon R; Lamberts SW
J Clin Endocrinol Metab; 1997 Aug; 82(8):2622-8. PubMed ID: 9253344
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of blood chromogranin A measurement in neuroendocrine tumours.
Seregni E; Ferrari L; Bajetta E; Martinetti A; Bombardieri E
Ann Oncol; 2001; 12 Suppl 2():S69-72. PubMed ID: 11762355
[TBL] [Abstract][Full Text] [Related]
4. Chromogranin-A as a serum marker for neuroendocrine tumors: comparison with neuron-specific enolase and correlation with immunohistochemical findings.
Giovanella L; La Rosa S; Ceriani L; Uccella S; Erba P; Garancini S
Int J Biol Markers; 1999; 14(3):160-6. PubMed ID: 10569138
[TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings?
Angelsen A; Syversen U; Haugen OA; Stridsberg M; Mjølnerød OK; Waldum HL
Prostate; 1997 Jan; 30(1):1-6. PubMed ID: 9018329
[TBL] [Abstract][Full Text] [Related]
6. Serum chromogranin-A in advanced prostate cancer.
Ferrero-Poüs M; Hersant AM; Pecking A; Brésard-Leroy M; Pichon MF
BJU Int; 2001 Nov; 88(7):790-6. PubMed ID: 11890255
[TBL] [Abstract][Full Text] [Related]
7. Immunoradiometric assay of chromogranin A in the diagnosis of small cell lung cancer: comparative evaluation with neuron-specific enolase.
Giovanella L; Ceriani L; Bandera M; Garancini S
Int J Biol Markers; 2001; 16(1):50-5. PubMed ID: 11288956
[TBL] [Abstract][Full Text] [Related]
8. Neuroendocrine serum tumour markers in hormone-resistant prostate cancer.
Hvamstad T; Jordal A; Hekmat N; Paus E; Fosså SD
Eur Urol; 2003 Aug; 44(2):215-21. PubMed ID: 12875941
[TBL] [Abstract][Full Text] [Related]
9. The prognostic significance of circulating neuroendocrine markers chromogranin a, pro-gastrin-releasing peptide and neuron-specific enolase in patients with advanced non-small-cell lung cancer.
Nisman B; Heching N; Biran H; Barak V; Peretz T
Tumour Biol; 2006; 27(1):8-16. PubMed ID: 16340245
[TBL] [Abstract][Full Text] [Related]
10. A new human chromogranin 'A' immunoradiometric assay for the diagnosis of neuroendocrine tumours.
Bernini GP; Moretti A; Ferdeghini M; Ricci S; Letizia C; D'Erasmo E; Argenio GF; Salvetti A
Br J Cancer; 2001 Mar; 84(5):636-42. PubMed ID: 11237384
[TBL] [Abstract][Full Text] [Related]
11. Circulating neuroendocrine markers in patients with prostate carcinoma.
Berruti A; Dogliotti L; Mosca A; Bellina M; Mari M; Torta M; Tarabuzzi R; Bollito E; Fontana D; Angeli A
Cancer; 2000 Jun; 88(11):2590-7. PubMed ID: 10861438
[TBL] [Abstract][Full Text] [Related]
12. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus.
Yao JC; Pavel M; Phan AT; Kulke MH; Hoosen S; St Peter J; Cherfi A; Öberg KE
J Clin Endocrinol Metab; 2011 Dec; 96(12):3741-9. PubMed ID: 21994954
[TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine differentiation in colorectal carcinomas.
Syversen U; Halvorsen T; Mårvik R; Waldum HL
Eur J Gastroenterol Hepatol; 1995 Jul; 7(7):667-74. PubMed ID: 8590163
[TBL] [Abstract][Full Text] [Related]
14. Impact of chromogranin A measurement in the work-up of neuroendocrine tumors.
Baudin E; Bidart JM; Bachelot A; Ducreux M; Elias D; Ruffié P; Schlumberger M
Ann Oncol; 2001; 12 Suppl 2():S79-82. PubMed ID: 11762357
[TBL] [Abstract][Full Text] [Related]
15. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors.
Bajetta E; Ferrari L; Martinetti A; Celio L; Procopio G; Artale S; Zilembo N; Di Bartolomeo M; Seregni E; Bombardieri E
Cancer; 1999 Sep; 86(5):858-65. PubMed ID: 10463986
[TBL] [Abstract][Full Text] [Related]
16. Plasma chromogranin A in patients with sporadic gastro-entero-pancreatic neuroendocrine tumors or multiple endocrine neoplasia type 1.
Peracchi M; Conte D; Gebbia C; Penati C; Pizzinelli S; Arosio M; Corbetta S; Spada A
Eur J Endocrinol; 2003 Jan; 148(1):39-43. PubMed ID: 12534356
[TBL] [Abstract][Full Text] [Related]
17. Chromogranin A and neuron-specific enolase in neuroblastoma: Correlation to stage and prognostic factors.
Georgantzi K; Sköldenberg EG; Stridsberg M; Kogner P; Jakobson Å; Janson ET; Christofferson RHB
Pediatr Hematol Oncol; 2018 Mar; 35(2):156-165. PubMed ID: 29737901
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of neuroendocrine serum markers and PSA in irradiated patients with pN0 localized prostate cancer.
Lilleby W; Paus E; Skovlund E; Fosså SD
Prostate; 2001 Feb; 46(2):126-33. PubMed ID: 11170140
[TBL] [Abstract][Full Text] [Related]
19. Choice of tumour markers in patients with neuroendocrine tumours is dependent on the histological grade. A marker study of Chromogranin A, Neuron specific enolase, Progastrin-releasing peptide and cytokeratin fragments.
Korse CM; Taal BG; Vincent A; van Velthuysen ML; Baas P; Buning-Kager JC; Linders TC; Bonfrer JM
Eur J Cancer; 2012 Mar; 48(5):662-71. PubMed ID: 21945100
[TBL] [Abstract][Full Text] [Related]
20. Chromogranin A and neurone-specific enolase variations during the first 3 months of abiraterone therapy predict outcomes in patients with metastatic castration-resistant prostate cancer.
Fan L; Wang Y; Chi C; Pan J; Xun S; Xin Z; Hu J; Zhou L; Dong B; Xue W
BJU Int; 2017 Aug; 120(2):226-232. PubMed ID: 28107595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
